Latest NewLimit News & Updates

See the latest news and media coverage for NewLimit. We track all announcements, press releases, and industry mentions in real time, all in one place.

NewLimit

Biotechnology company developing epigenetic reprogramming medicines for age-related diseases

newlimit.com

Headquarters: South San Francisco, United States
Founded year: 2022
Company type: Private company
Number of employees: 50–67
Industry: Biotechnology & Medical Research

Last updated September 16

Latest news about NewLimit

In short: NewLimit raised $435M in Series C funding to advance epigenetic reprogramming medicines toward human trials.

Company announcements

June 9 NewLimit

NewLimit publishes 2026 progress update

AI systems doubled discovery rate, advancing three therapeutic programs and a clinical candidate.

June 2 NewLimit

NewLimit raises $435M for longevity medicine trials

The Series C was led by Founders Fund, and the first medicine reverses cell age in old human liver cells, with trials starting next year.

March 27 NewLimit

NewLimit announces January-February 2026 progress

Discovers new reprogramming payloads restoring hepatocyte functions, advances manufacturing of first candidate, builds AI system doubling discovery rate, and develops kidney endothelial model.

January 6 NewLimit

NewLimit reviews 2025 reprogramming achievements

Built first preclinical candidate restoring youthful hepatocyte functions, developed AI doubling discoveries per dollar, discovered 30+ payloads, launched vascular program.

Media coverage

September 16 PR Newswire

Investors pour over $30bn into longevity biotech as report predicts longevity drugs from 2035

Eli Lilly backed NewLimit's $435 million Series C in June 2026, which valued the epigenetic reprogramming company at $3.1 billion. In July 2026, Takeda committed...

September 7 搜狐

$636 million sets a new high for the longevity market! Capital frenzy, betting on human trials, financing difficulties for small and medium-sized startups intensify

In Q2 2026, global funding in the longevity sector reached $636 million, nearly doubling quarter-on-quarter, appearing even hotter; but excluding NewLimit's single $435 million deal, the remaining companies received almost the same amount as six months ago—money is accelerating towards the few top companies "able to enter humans," while newcomers and small and medium-sized institutions are being squeezed out of the table...

September 1 MoneyDJ

"US Stock Thematic Weekly Report" Aging Management and Longevity Medicine - SYK, BSX

MoneyDJ News 2026-09-01 15:54:25 Digital Content Center Published NewLimit The signal worth remembering this week is that NewLimit ranked in the top tier of annual private financing with $435 million in BioBucks' 2026 biotech venture capital funding tracking, second only to Isomorphic Labs and Earendil...

June 5 Inc.

A $435 Million Bet on 'Reversing Aging'

Biotech startup NewLimit secures a major funding round after claiming a 'breakthrough discovery' of a prototype medicine that rewinds cellular aging in the liver.

Never miss news about NewLimit

Track NewLimit and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NewLimit competitors & trending companies

Browse news for competitors to NewLimit and other trending companies.